Hester Biosciences Q4 Results 2026: Date, Revenue, PAT And Analyst Outlook

Tue Apr 14 2026

Hester Biosciences (NSE: HESTERBIO) is set to announce its Q4 FY26 (January–March 2026) results on May 12, 2026. Trading at Rs 1,680 as of April 2026 — down -36% from its 52-week high of Rs 2,650 — the stock enters this pivotal results event having already corrected meaningfully from peak levels. Q4 FY26 delivers the full-year FY26 performance and the first formal FY27 management guidance.

This preview covers the confirmed results date, analyst consensus estimates, five key performance factors, five risks to monitor, analyst ratings, and the complete share price outlook for Hester Biosciences ahead of Q4 FY26 results.

Get free investment predictions from SEBI-registered analysts on Univest.

Table of Contents

Hester Biosciences Q4 Results 2026 Date

The Hester Biosciences Q4 FY26 results date is May 12, 2026. The board will approve Q4 and full-year FY26 financial results, consider a final dividend for FY26, and provide management’s first formal FY27 business outlook.

Company	Q4 Results Date	Key Metric to Watch
TCS	April 9, 2026 (Declared)	FY27 CC guidance + deal TCV
Infosys	April 23, 2026	CC revenue growth range
HCL Technologies	April 22, 2026	CC growth + EBIT margin
HDFC Bank	April 19, 2026	NIM recovery + loan growth
Hester Biosciences	May 12, 2026	See estimates below

Why Q4 FY26 Matters

Q4 FY26 is the final quarter of FY2025–26 and carries the highest informational weight of any quarterly result. Beyond the Q4 standalone performance, the Hester Biosciences board on May 12, 2026 will deliver the complete FY26 annual performance, a final dividend recommendation, and the first formal FY27 guidance commentary — making this the single most important quarterly event for Hester Biosciences investors.

For Hester Biosciences in the Veterinary Vaccines / Pharma sector, Q4 captures the peak-season demand dynamics that typically deliver the quarter’s strongest operating leverage when execution conditions are favourable.

Hester Biosciences Q4 FY26 Earnings Estimates

Hester Biosciences Q4 FY26 analyst estimates — Revenue Rs 185 Cr, PAT Rs 22 Cr | univest.in

Access premium analyst research on Univest.

Metric	Q4 FY26 Estimate	Q3 FY26 Actual	Trend
Revenue	Rs 185 Cr	Rs 165 Cr	Sequential improvement expected
Net Profit (PAT)	Rs 22 Cr	Rs 19 Cr	Normalisation in progress
Operating Margin	EBITDA 18%	Q3 FY26 level	Stable to improving
Volume / Revenue Growth	+12% volume YoY	Prior quarter	YoY improvement expected
Final Dividend (Expected)	Rs 5	FY26 interim dividends	Board decision on May 12, 2026

Screen Hester Biosciences live on the Univest Screener — real-time fundamentals, FII/DII flows, and analyst ratings.

Download the Univest iOS App or Univest Android App for live Q4 result alerts.

5 Key Factors Driving Hester Biosciences Q4 FY26 Performance

1. India Branded Generic Growth

India pharmaceutical market growing at 8-10% annually. Q4 captures year-end prescription momentum.

2. US Generic Revenue

ANDA approvals and generic launches drive US export revenue. First-to-file paragraphs provide 180-day exclusivity.

3. CDMO Revenue

Contract manufacturing for global innovators provides long-term, high-margin revenue.

4. New Product Launches

New OTC and branded generic launches in India expand domestic market share.

5. API Cost Normalisation

Global API price moderation benefits formulation company gross margins.

5 Risks to Watch in Hester Biosciences Q4 FY26

Risk 1: Input Cost Volatility

Raw material and input cost changes can compress margins unexpectedly.

Risk 2: Revenue Concentration Risk

Customer or geographic concentration creates quarterly variance.

Risk 3: Competitive Pressure

Intensified sector competition may require price or volume concessions.

Risk 4: Regulatory Environment

Policy and regulatory changes can create compliance cost or revenue risks.

Risk 5: Macroeconomic Sensitivity

Global and domestic conditions — tariffs, interest rates, consumption — affect demand.

Hester Biosciences Share Price and Analyst Ratings

Parameter	Value
CMP (April 2026)	Rs 1,680
52-Week High	Rs 2,650
52-Week Low	Rs 1,480
1-Year Return	-36%
Market Cap	Rs 1,200 Cr
Sector	Veterinary Vaccines / Pharma
NSE Ticker	HESTERBIO
Q4 Results Date	May 12, 2026

Brokerage	Rating	Thesis Summary
Motilal Oswal	BUY	Q4 recovery potential; sector tailwinds intact
YES Securities	ADD	Earnings inflection expected; FY27 guidance key
Kotak Institutional	NEUTRAL	Fair valued at current levels; execution key

Conclusion

Hester Biosciences Q4 FY26 results on May 12, 2026 will be the most important quarterly event of FY26. At Rs 1,680 — down -36% from its 52-week high of Rs 2,650 — the stock has already priced in significant headwinds. Revenue above Rs 185 Cr with EBITDA 18% would constitute a beat versus analyst consensus. Management’s FY27 guidance is the primary re-rating catalyst that determines whether the current level represents an entry opportunity.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All data sourced from publicly available information. Verify before investing. Consult a SEBI-registered financial advisor before making investment decisions.

For more Q4 FY26 results previews, visit Univest Blogs.

Frequently Asked Questions

Q: When is Hester Biosciences Q4 results 2026 date?

Hester Biosciences Q4 FY26 results date is May 12, 2026. The board will approve the audited Q4 and full-year FY26 financial results, consider a final dividend, and provide FY27 guidance.

Q: What is Hester Biosciences Q4 FY26 revenue estimate?

Analyst consensus Q4 FY26 revenue estimate for Hester Biosciences is Rs 185 Cr. Q3 FY26 actual revenue was Rs 165 Cr. Actual results may differ based on operating conditions.

Q: What is Hester Biosciences share price ahead of Q4 results?

Hester Biosciences trades at Rs 1,680 as of April 2026. 52-week high is Rs 2,650; 52-week low is Rs 1,480. 1-year return is -36%. Market cap is Rs 1,200 Cr.

Q: Will Hester Biosciences declare a dividend in Q4 2026?

Hester Biosciences is expected to declare Rs 5 as final dividend for FY26, subject to board approval on May 12, 2026 and subsequent AGM shareholder approval.

Q: Which analysts have a Buy rating on Hester Biosciences?

Motilal Oswal has a BUY rating and YES Securities has an ADD rating on Hester Biosciences based on publicly available research. Check the Univest Screener for the latest analyst ratings.

Q: What were Hester Biosciences Q3 FY26 results?

Hester Biosciences reported Q3 FY26 revenue of Rs 165 Cr and PAT of Rs 19 Cr. The Q4 FY26 results on May 12, 2026 provide the full-year FY26 comparison and first FY27 guidance.

Q: When do TCS and Infosys announce Q4 results 2026?

TCS declared Q4 FY26 results on April 9, 2026. HCL Technologies declared on April 22. HDFC Bank declared on April 19. Infosys Q4 FY26 results are scheduled for April 23, 2026.

Q: Is Hester Biosciences a good investment ahead of Q4 results?

This article does not constitute investment advice. Hester Biosciences trades at Rs 1,680 — down -36% from its peak. Analyst consensus Q4 revenue estimate is Rs 185 Cr and PAT estimate is Rs 22 Cr. Review the five factors and five risks above. Consult a SEBI-registered financial advisor before investing.